微信扫码关注“小狗文献”

即刻体验更多权益

文献多,下载快,翻译准

首页 > 医学词汇大全 > Angiotensin II receptor blockers
Angiotensin II receptor blockers

心血管

关键词心血管 临床研究术语 阻滞剂

词汇介绍

拓展阅读

解析

angiotensin  /,ændʒɪə(ʊ)'tensɪn/  /,ændʒɪo'tɛnsən/

释义   n. 血管紧张肽;血管紧缩素

例句   ACE inhibitors work by blocking the action of a compound in the body called angiotensin converting enzyme.

ACE抑制剂是通过阻断体内的血管紧张素转换酶复合物的活性来发挥作用的。

 

receptor   /rɪ'septə/  /rɪ'sɛptɚ/  

释义   n. [生化] 受体;接受器;感觉器官

例句   This article reviewed the advancement in distribution, signal transduction and regulation mode of ETB receptor.

本文对ETB 受体的分布、信号途径、调节方式的研究进展予以综述。

 

blocker  /'blɑkɚ/  

释义   n. 阻挡者;堵塞物;

例句   Objective To evaluate nimodipine, a calcium channel blocker, in the treatment of unstable bladder.

目的探讨钙通道阻滞剂尼莫地平治疗不稳定膀胱的临床疗效。

概述

肾素-血管紧张素系统,通过血管紧张素II(AngII)对正常血压及电解质平衡起着重要的调节作用,并对高血压、心力衰竭、心脏肥大、肾衰、动脉粥样硬化等心血管疾病有着密切的关系。血管紧张素转换酶(ACE)抑制剂,如卡托普利等阻断了AgnII生成的一条途径,具有明显的降压效果。但血管紧张素转换酶被抑制后,体内缓激肽浓度上升,P物质增多,不可避免地产生干咳、血管水肿等不良反应。此外,由于体内AngII不仅可以通过血管紧张素转换酶生成,还可以通过其他途径产生,为最大限度地抑制RAS,最直接、最彻底的手

Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction复制标题

心肌梗死患者肾功能损害的血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂

发表时间:2016-04-12

影响因子:18.6

作者: Marie Evans

期刊:J. Am. Coll. Cardiol.

Chronic kidney disease (CKD) is an important risk factor for cardiovascular disease; the cardiovascular risk increases even with slightly decreased estimated glomerular filtration rate (eGFR) and becomes 8-fold higher in patients with severe renal dysfunction. Patients with CKD also have worse outcomes after an acute cardiovascular event compared with patients with normal renal function. Even though patients with low eGFR are considered a high risk group, the evidence for treating these patients with ACEI/ARB after MI is almost nonexistent as they were excluded from most trials. Importantly, ACEI or ARB use can also potentially result in acute kidney injury (AKI) and hyperkalemia, adverse events believed to be more common in CKD patients, perhaps discouraging clinicians from treating these patients with these agents. However, a recent observational study among U.S. veterans with CKD showed that use of an ACEI or ARB for any indication was associated with a 19% lower all-cause mortality. We aimed to investigate current use of ACEI and ARBtherapy after MI to assess long-term outcomes associated with their use in routine clinical practice across different risk profiles, including the entire spectrum of estimated glomerular function.

译文

慢性肾脏病(CKD)是心血管疾病的重要危险因素;即使肾小球滤过率(eGFR)略有降低,心血管风险也会增加,严重肾功能不全患者的心血管风险也会增加8倍。与肾功能正常的患者相比,急性心血管事件后CKD患者的预后更差。即使低eGFR患者被认为是高风险组,但MI后治疗这些ACEI / ARB患者的证据几乎不存在,因为他们被排除在大多数试验之外。重要的是,ACEI或ARB的使用也可能导致急性肾损伤(AKI)和高钾血症,据信在CKD患者中更常见的不良事件,可能会阻碍临床医生用这些药物治疗这些患者。然而,美国退伍军人CKD最近的一项观察性研究显示,任何适应症使用ACEI或ARB与全因死亡率降低19%相关。我们的目的是调查ACEI和ARB的当前用途心肌梗死后的治疗,以评估与不同风险概况的常规临床实践中使用相关的长期结果,包括估计的肾小球功能的整个范围。